Xenon Pharmaceuticals Hits New 52-Week High at $46.99

Xenon Pharmaceuticals, Inc. has reached a significant milestone by hitting a new 52-week high of USD 46.99 on February 27, 2026. This achievement marks a notable increase from its 52-week low of USD 26.74, reflecting a year-to-date performance of 13.05%. As a small-cap company in the Pharmaceuticals & Biotechnology sector, Xenon Pharmaceuticals has a market capitalization of approximately USD 3,263 million. Despite its recent price surge, the company remains in a loss-making position, with a return on equity of -54.75%. The stock currently does not offer a dividend yield, and its price-to-book ratio stands at 5.83. In comparison to the broader market, Xenon's performance lags behind the S&P 500, which has seen a return of 17.36% over the same period. The company's debt-to-equity ratio is reported at -0.82, indicating a unique financial structure. Overall, the recent price movement highlights Xenon Pharmaceuticals' position within the competitive landscape of the biotechnology industry.